Medical Treatment of Cardiovascular Disease in the Elderly

  • Lionel H. Opie
  • T. A. Mabin
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 76)


Elderly patients constitute a group in whom diseases are “creeping up.” These diseases may not be cardiovascular but influence the general level of activity of the patient and the general feeling of health or ill-health. Therefore, the patient may apparently present with a cardiovascular problem when the real diagnosis lies elsewhere.


Mitral Valve Aortic Stenosis Infective Endocarditis Transient Ischemic Attack Systolic Hypertension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ouslander JG. Drug therapy in the elderly. Ann Intern Med 95:711–722, 1981.PubMedCrossRefGoogle Scholar
  2. 2.
    Amery A, Brixko P, Clement D, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly Trial. Lancet 1:1349–1354, 1985.PubMedCrossRefGoogle Scholar
  3. 3.
    Dall JLC. Maintenance digoxin in elderly patients. Br Med J 2:705–706, 1070.CrossRefGoogle Scholar
  4. 4.
    Causack, B, Kelly J, O’Malley K, et al. Digoxin in the elderly: Pharmacokinetic consequences of old age. Clin Pharmacol Ther 25(6):772–776, 1979.Google Scholar
  5. 5.
    Ewy GA, Kapadia GG, and Yao L. Digoxin metabolism in the elderly. Circulation 39:449–453, 1969.PubMedCrossRefGoogle Scholar
  6. 6.
    Berman W Jr and Musselman J. The relationship of age to the metabolism and protein binding of digoxin in sheep. J Pharmacol Exp Ther 208(2):263–266, 1979.PubMedGoogle Scholar
  7. 7.
    Gerstenblith G, Spurgeon HA, Froehlich JP, et al. Diminished inotropic responsiveness to ouabain in aged rat myocardium. Circ Res 44(4):517–523, 1979.PubMedCrossRefGoogle Scholar
  8. 8.
    Guarnieri T, Spurgeon H, Froehlich JP, et al. Diminished inotropic responses but unaltered toxicity to acetylsbrophanthidin in the senescent beagle. Circulation 60(7):1548–1554, 1979.PubMedCrossRefGoogle Scholar
  9. 9.
    Whiting B, Wandless I, Summer DJ, and Goldberg A. Computer-assisted review of digoxin therapy in the elderly. Br Heart J 40(1):8–13, 1978.PubMedCrossRefGoogle Scholar
  10. 10.
    Castleden et al. Br J Clin Pharmacol 2:303, 1975.PubMedCrossRefGoogle Scholar
  11. 11.
    Vestal RE, Wood AJ, and Shand DG. Reduced beta-adrenoceptor sensitivity in the elderly. Clin Phar Ther 26(2):181–186, 1979.Google Scholar
  12. 12.
    Schocken DD and Roth GS. Reduced beta-adrenergic receptor concentrations in ageing man. Nature 267 (5614):856–858, 1977.PubMedCrossRefGoogle Scholar
  13. 13.
    Yin FCP, Spurgeon HA, Raizes GS, et al. Age-associated decrease in chronotropic response to isoproterenol (abstract). Circulation 54 11:167, 1976.Google Scholar
  14. 14.
    Cokkinos DV, Tsartsalis GD, Heimonas ET, and Gardikas CD. Comparison of the inotropic action of digitalis and isoproterenol in younger and older individuals. Am Heart J 100(6 Pt 1):802–806, 1980.PubMedCrossRefGoogle Scholar
  15. 15.
    Guarnieri T, Filburn CR, Zitnik G, et al. Contractile and biochemical correlates of beta-adrenergic stimulation of the aged heart. Am J Physiol 239(4):H501-H508, 1980.Google Scholar
  16. 16.
    Nation RI, Triggs EJ, and Selig M. Lignocaine kinetics in cardiac patients and aged subjects. Br J Clin Pharmacol 4(4):439–448, 1977.PubMedCrossRefGoogle Scholar
  17. 17.
    Reidenberg MM, Camacho M, Kluger J, and Drayer DE. Aging and renal clearance of procainamide and acetylprocainamide. Clin Pharmacol Ther 28(6):732–735, 1980.PubMedCrossRefGoogle Scholar
  18. 18.
    Ochs HR, Greenblatt DJ, Woo E, and Smith TW. Reduced quinidine clearance in eldery persons. Am J Cardiol 42(3):481–485, 1978.PubMedCrossRefGoogle Scholar
  19. 19.
    Shepherd AM, Hewick DS, Moreland TA, and Stevenson IH. Age as a determinant of sensitivity to warfarin. Br J Clin Pharmacol 4:315–320, 1977.PubMedCrossRefGoogle Scholar
  20. 20.
    Ashraf N, Locksley R, and Arieff AI. Thiazide-induced hyponatremia associated with death or neurologic damage in outpatients. Am J Med 70:1163–1168, 1981.PubMedCrossRefGoogle Scholar
  21. 21.
    Epstein M and Hollenberg NK. Age as determinant of renal sodium conservation in normal man. J Lab Clin Med 87:411–417, 1976.PubMedGoogle Scholar
  22. 22.
    Zacharias FJ and Cruickshank JM. Treating the elderly hypertensive. Acta Therap 5:179–192, 1979.Google Scholar
  23. 23.
    Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. Brit. Med. J. 293:1145–1148, 1986.CrossRefGoogle Scholar
  24. 24.
    Bühler FR, Bolli P, Erne P, et al. Position of calcium antagonists in antihypertensive therapy. J Cardiovasc Pharmacol 7 (suppl 4): 521-S27, 1985.Google Scholar
  25. 25.
    Ben-Ishay D, Leibel B, and Stessman J. Calcium channel blockers in the management of hypertension in the elderly. Am J Med 81 (Suppl 6A):30–34, 1986.PubMedCrossRefGoogle Scholar
  26. 26.
    Harris R. The old heart. In G Bourne (ed), Hearts and Heart-like Organs, Vol. 3. New York: Academic Press, 1980, pp 159–188.Google Scholar
  27. 27.
    Chaudhry AY, Bing RF, Castelden CM, et al. The effect of ageing on the response to frusemide in normal subjects. Eur J Clin Pharmacol 27:303–306, 1984.PubMedCrossRefGoogle Scholar
  28. 28.
    Andreasen F, Hansen U, Husted SE, et al. The influence of age on renal and extrarenal effects of frusemide. Brit J Clin Pharmac 18:65–74, 1984.CrossRefGoogle Scholar
  29. 29.
    Hamdy RC. Diuretic Therapy in the Older Patient. Philadelphia: Smith, Kline and French, 1978, pp 47–50.Google Scholar
  30. 30.
    Lye M. Body potassium content and capacity of elderly individuals with and without cardiac failure. Cardiovasc Res 16:22–25, 1982.PubMedCrossRefGoogle Scholar
  31. 31.
    Gersh BJ, Kronmal RA, Schaff HV, et al. Long-term (5 year) results of coronary bypass surgery in patients 65 years old or older: A report from the Coronary Artery Surgery Study. Circulation 68 (Suppl II): 11–190–11–199, 1983.Google Scholar
  32. 32.
    Knapp WS, Douglas JS, Craver JM, et al. Efficacy of coronary bypass grafting in elderly patients with coronary artery disease. Am J Cardiol 47:923–930, 1981.PubMedCrossRefGoogle Scholar
  33. 33.
    Wintzen AR, Tijssen JGP, deVries WA, et al. Risk of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Second report of the sixty plus reinfarction study research group. Lancet 1:64–68, 1982.Google Scholar
  34. 34.
    Hawkins CM, Richardson DW, Vokonas PS. Effect of propranolol in reducing mortality in older myocardial infarction patients. The Beta-Blocker Heart Attack Trial experience. Circulation 67 (Suppl I):I-94-I97, 1983.Google Scholar
  35. 35.
    Gundersen, T. Abrahamsen AM, Kjekshus J, and Ronnevik PK. Timolol-related reduction in mortality and reinfarction in patients aged 65–75 years surviving acute myocardial infarction. Circulation 66:1179–1184, 1982.PubMedCrossRefGoogle Scholar
  36. 36.
    Olsson G, Rehnqvist N, Sjogren A, et al. Long-term treatment with metoprolol after myocardial infarction: Effect on 3 year mortality and morbidity. J Am Coll Cardiol 5:1428–1437, 1985.PubMedCrossRefGoogle Scholar
  37. 37.
    Schocken DD, Blumenthal JA, Port S. et al. Physical conditioning and left ventricular performance in the elderly: Assessment by radionuclide angiocardiography. Am J Cardiol 52:359–364, 1983.PubMedCrossRefGoogle Scholar
  38. 38.
    The Anturane Reinfarction Trial Research Group. Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 302(5):250–256, 1980.CrossRefGoogle Scholar
  39. 39.
    Anturane Reinfarction Italian Study. Sulphinpyrazone in postmyocardial infarction. Lancet 1:237–242, 1982.Google Scholar
  40. 40.
    Aspirin Myocardial Infarction Study Research Group. A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 243:661–669, 1980.CrossRefGoogle Scholar
  41. 41.
    Persantine-Aspirin Reinfarction Study Research Group. Persantine and aspirin in coronary heart disease. Circulation 62:449–461, 1980.CrossRefGoogle Scholar
  42. 42.
    Murphy ES, Lawson RM, Starr A, et al. Severe aortic stenosis in patients 60 yeras of age and older: left ventricular function and 10-year survival after valve replacement. Circulation 64 (Suppl II):II-184–II–188, 1981.Google Scholar
  43. 43.
    Commerfold PJ, Curcio A, Albanese M, and Beck W. Aortic valve replacement in the elderly. South Afr Med J 59:975–976, 1981.Google Scholar
  44. 44.
    De Bono AHB, English TAH, and Milstein BB. Heart valve replacement in the elderly. Br Med J 2:917–919, 1978.PubMedCrossRefGoogle Scholar
  45. 45.
    Waller BF and Roberts WC. Cardiovascular disease in the very elderly. Analysis of 40 necropsy patients aged 90 years or over. Am J Cardiol 51:403–421, 1983.PubMedCrossRefGoogle Scholar
  46. 46.
    Kolibash AJ, Bush CA, Fotana MB, et al. Mitral valve prolapse syndrome: Analysis of 62 patients aged 60 years and older. Am J Cardiol 52:534–539, 1983.PubMedCrossRefGoogle Scholar
  47. 47.
    Templeton GH, Platt MR, Willerson JT, and Weisfeldt MI. Influence of aging on left ventricular hemodynamics and stiffness in beagles. Circ Res 44:189–194, 1979.PubMedCrossRefGoogle Scholar
  48. 48.
    Camm AJ, Evans KE, Ward DE, and Martin A. The rhythm of the heart in active elderly subjects. Am Heart J 99:598–603, 1980.PubMedCrossRefGoogle Scholar
  49. 49.
    Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 229:53–59, 1978.CrossRefGoogle Scholar
  50. 50.
    Fields WS, Lemak NA, Frankowski KF, et al. Controlled trial of aspirin in cerebral Uchemia. Circulation 62 (Suppl V):V90—V96, 1980.Google Scholar

Suggested Readings

  1. Anderson GJ. Clinical clues to digitalis toxicity. Geriatrics 35(6):57–65, 1980.PubMedGoogle Scholar
  2. Harris R. The Management of Geriatric Cardiovascular Disease. Philadelphia: Lippincott, 1970.Google Scholar
  3. Lee PV. Drug therapy in the elderly: The clinically pharmacology of aging. Clin Exper Res 2:39–42.Google Scholar
  4. Lowenthal DT and Affrime MB. Cardiovascular drugs for the geriatric patient. Cardiology 36:65–74, 1981.Google Scholar
  5. Mitenko PA, Comfort A, and Crooks J (eds). Drugs and the elderly. Proceedings of a symposium. J Chronic Dis 36(1), 1983.Google Scholar
  6. O’Hanrahan M and O’Malley K. Compliance with drug treatment. Br Med J 283:298–300, 1981.CrossRefGoogle Scholar
  7. Swift CG. Clinical pharmacology in the elderly. Scott Med J 24:221–225, 1979.PubMedGoogle Scholar
  8. Unverferth DV, Magorien RD, and Leier CV. Drug regimens for congestive heart failure. Geriatrics 35(7):26–33, 1980.PubMedGoogle Scholar
  9. Vestal RE. Drug use in the elderly: A review of problems and special considerations. Drugs 16:358–382, 1978.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1987

Authors and Affiliations

  • Lionel H. Opie
  • T. A. Mabin

There are no affiliations available

Personalised recommendations